Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Cancer Cell. 2011 Oct 18;20(4):457-71. doi: 10.1016/j.ccr.2011.09.001.
Androgen receptor (AR) is reactivated in castration-resistant prostate cancer (CRPC) through mechanisms including marked increases in AR gene expression. We identify an enhancer in the AR second intron contributing to increased AR expression at low androgen levels in CRPC. Moreover, at increased androgen levels, the AR binds this site and represses AR gene expression through recruitment of lysine-specific demethylase 1 (LSD1) and H3K4me1,2 demethylation. AR similarly represses expression of multiple genes mediating androgen synthesis, DNA synthesis, and proliferation while stimulating genes mediating lipid and protein biosynthesis. Androgen levels in CRPC appear adequate to stimulate AR activity on enhancer elements, but not suppressor elements, resulting in increased expression of AR and AR repressed genes that contribute to cellular proliferation.
雄激素受体(AR)在去势抵抗性前列腺癌(CRPC)中通过包括 AR 基因表达显著增加的机制被重新激活。我们确定了 AR 第二内含子中的一个增强子,该增强子有助于在 CRPC 中低雄激素水平下增加 AR 的表达。此外,在雄激素水平升高的情况下,AR 结合该位点,并通过募集赖氨酸特异性去甲基化酶 1(LSD1)和 H3K4me1、2 去甲基化来抑制 AR 基因表达。AR 同样抑制介导雄激素合成、DNA 合成和增殖的多个基因的表达,同时刺激介导脂质和蛋白质生物合成的基因。CRPC 中的雄激素水平似乎足以刺激增强子元件上的 AR 活性,但不能抑制抑制子元件上的 AR 活性,从而导致 AR 表达增加和 AR 抑制基因表达增加,这有助于细胞增殖。